Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., a leading biotechnology firm headquartered in the United States, focuses on developing innovative therapies for rare diseases and chronic conditions. Founded in 2007, the company has made significant strides in the field of RNA interference (RNAi) technology, positioning itself as a pioneer in this transformative area of medicine. With a robust pipeline of products, Dicerna is dedicated to addressing unmet medical needs through its unique approach to gene silencing. The company’s core offerings include therapies targeting liver diseases and other genetic disorders, distinguished by their precision and efficacy. Dicerna's commitment to advancing healthcare has garnered recognition within the industry, solidifying its market position as a key player in the biotechnology sector.
DitchCarbon Score
How does Dicerna Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dicerna Pharmaceuticals, Inc.'s score of 73 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dicerna Pharmaceuticals, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Novo Nordisk A/S, which means that any climate commitments or emissions data may be inherited from its parent organisation. Dicerna's climate initiatives are aligned with those of Novo Nordisk A/S, which has established various sustainability targets. However, specific reduction targets or achievements for Dicerna itself have not been disclosed. The company is part of a broader corporate family that is engaged in significant climate action, including participation in initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are led by Novo Nordisk A/S. As a subsidiary, Dicerna Pharmaceuticals is expected to adhere to the sustainability commitments set forth by Novo Nordisk, which include ambitious goals for reducing greenhouse gas emissions across all scopes. However, without specific data or targets from Dicerna, the details of their individual climate commitments remain vague.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 86,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 75,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dicerna Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
